Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

1479304

USP

Oseltamivir phosphate

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C16H28N2O4 ·H3PO4
Numero CAS:
Peso molecolare:
410.40
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

oseltamivir

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1
PGZUMBJQJWIWGJ-ONAKXNSWSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni


  • Neuraminidase Inhibition by Oseltamivir Phosphate: Oseltamivir phosphate′s mechanism as a neuraminidase inhibitor was highlighted in a study examining its effect on virus-neutralizing antibodies in influenza A-infected mice, demonstrating its impact on dosage and scheduling for effective flu treatment (Mikušová et al., 2022).

  • Oseltamivir Phosphate in Lung Cancer Research: Research explored the use of oseltamivir phosphate loaded into pegylated-Eudragit nanoparticles for lung cancer therapy, focusing on characterization, prolonged release, cytotoxicity profile, apoptosis pathways, and the anti-angiogenic effect, thereby expanding its application beyond traditional antiviral uses (Yurtdaş-Kırımlıoğlu et al., 2022).

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Zanamivir for assay European Pharmacopoeia (EP) Reference Standard

Y0001702

Zanamivir for assay

Zanamivir ≥98% (HPLC)

Sigma-Aldrich

SML0492

Zanamivir

Ribavirin antiviral

Sigma-Aldrich

R9644

Ribavirin

Cyclosporine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1092

Cyclosporine

Mupirocin ≥92% (HPLC), powder

Sigma-Aldrich

M7694

Mupirocin

Ritonavir ≥98% (HPLC)

Sigma-Aldrich

SML0491

Ritonavir

Ding Yuan Oh et al.
The Journal of antimicrobial chemotherapy, 69(9), 2458-2469 (2014-05-21)
The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many countries stockpiled
Henju Marjuki et al.
The Journal of infectious diseases, 210(3), 435-440 (2014-02-27)
Human infections caused by avian influenza A virus type subtype H7N9 have been associated with substantial morbidity and mortality. Emergence of virus variants carrying markers of decreased susceptibility to neuraminidase inhibitors was reported. Here we show that DAS181 (Fludase), an
Henju Marjuki et al.
Journal of virology, 89(10), 5419-5426 (2015-03-06)
Human infections by avian influenza A(H7N9) virus entail substantial morbidity and mortality. Treatment of infected patients with the neuraminidase (NA) inhibitor oseltamivir was associated with emergence of viruses carrying NA substitutions. In the NA inhibition (NI) assay, R292K conferred highly
Isabelle Marois et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 29(3), 973-987 (2014-11-22)
The clinical benefits of oseltamivir (Tamiflu) are well established, but the effects of antiviral treatment on the immune response are poorly understood. By use of flow cytometric analyses and the mouse model, we thoroughly investigated the impact of such a
Eric J Stavale et al.
PloS one, 10(3), e0121662-e0121662 (2015-03-19)
Our lead iminosugar analog called UV-4 or N-(9-methoxynonyl)-1-deoxynojirimycin inhibits activity of endoplasmic reticulum (ER) α-glucosidases I and II and is a potent, host-targeted antiviral candidate. The mechanism of action for the antiviral activity of iminosugars is proposed to be inhibition

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.